Explore the Potential with AI-Driven Innovation
The specialised, focused library is developed on demand with the most recent virtual screening and parameter assessment technology, guided by the Receptor.AI drug discovery platform. This approach exceeds the capabilities of traditional methods and offers compounds with higher activity, selectivity, and safety.
We pick out particular compounds from an extensive virtual database of more than 60 billion molecules. The preparation and shipment of these compounds are facilitated by our associate Reaxense.
Contained in the library are leading modulators, each labelled with 38 ADME-Tox and 32 physicochemical and drug-likeness qualities. In addition, each compound is illustrated with its optimal docking poses, affinity scores, and activity scores, giving a complete picture.
We employ our advanced, specialised process to create targeted libraries.
Fig. 1. The sreening workflow of Receptor.AI
Our methodology leverages molecular simulations to examine a vast array of proteins, capturing their dynamics in both isolated forms and in complexes with other proteins. Through ensemble virtual screening, we thoroughly account for the protein's conformational mobility, identifying critical binding sites within functional regions and distant allosteric locations. This detailed exploration ensures that we comprehensively assess every possible mechanism of action, with the objective of identifying novel therapeutic targets and lead compounds that span a wide spectrum of biological functions.
Our library distinguishes itself through several key aspects:
partner
Reaxense
upacc
P98175
UPID:
RBM10_HUMAN
Alternative names:
G patch domain-containing protein 9; RNA-binding motif protein 10; RNA-binding protein S1-1
Alternative UPACC:
P98175; A0A0A0MR66; C4AM81; Q14136; Q5JRR2; Q9BTE4; Q9BTX0; Q9NTB1
Background:
RNA-binding protein 10, also known as G patch domain-containing protein 9 and RNA-binding motif protein 10, plays a crucial role in post-transcriptional processing, particularly in mRNA splicing. It exhibits a strong affinity for RNA homopolymers, favoring poly(G) and poly(U) over poly(A), and is known to bind specific miRNA hairpins.
Therapeutic significance:
Linked to TARP syndrome, characterized by a combination of Robin sequence, talipes equinovarus, and cardiac defects, RNA-binding protein 10's involvement in this genetic disorder underscores its potential as a target for therapeutic intervention. Understanding the role of RNA-binding protein 10 could open doors to potential therapeutic strategies.